Open Access

Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells

  • Authors:
    • Xiumin Lu
    • Wenjing Zhang
    • Yu Liu
    • Meimei Liu
  • View Affiliations

  • Published online on: November 7, 2022     https://doi.org/10.3892/etm.2022.11682
  • Article Number: 746
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Evodiamine (EVO) is one of the main components extracted from Evodia rutaecarpa and has been reported to inhibit tumor growth by inhibiting proliferation and inducing apoptosis. Although the anticancer activity of evodiamine has been confirmed, the exact mechanism remains to be elucidated. In the present study, cancer stem‑like cells (CSCs) were successfully enriched from A549 cells by being cultured in serum‑free medium and characterized by detecting stemness markers. Expectedly, the addition of EVO inhibited proliferation, migration and invasion in A549 cells, demonstrating its inhibitory effects on the malignant behaviors of A549 cells. In CSCs derived from A549 cells, EVO treatment promoted cell proliferation while inhibiting migration and invasion. By detecting the hallmarks of the epithelial‑mesenchymal transition (EMT), including E‑cadherin, Vimentin, Slug and Snail via western blotting, it was revealed that EVO treatment inactivated the EMT process and potentially led to the loss of self‑renewal capacity of CSCs and promoted proliferation. By activating the EMT using TGF‑β pretreatment, EVO treatment downregulated the hallmarks of the EMT and led to inactivation of the EMT, indicating its potential mechanism of regulating CSCs via the EMT pathway. The findings suggested that modulation of the self‑renewal capacity of CSCs may affect malignant cancer behaviors following surgery. EVO exerts inhibitory effects not only on cancer cells but also on CSCs in non‑small‑cell lung cancer, and therefore could be used as a promising drug targeting CSCs.

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu X, Zhang W, Liu Y and Liu M: Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells. Exp Ther Med 24: 746, 2022
APA
Lu, X., Zhang, W., Liu, Y., & Liu, M. (2022). Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells. Experimental and Therapeutic Medicine, 24, 746. https://doi.org/10.3892/etm.2022.11682
MLA
Lu, X., Zhang, W., Liu, Y., Liu, M."Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells". Experimental and Therapeutic Medicine 24.6 (2022): 746.
Chicago
Lu, X., Zhang, W., Liu, Y., Liu, M."Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells". Experimental and Therapeutic Medicine 24, no. 6 (2022): 746. https://doi.org/10.3892/etm.2022.11682